Ewopharma’s Licensing Agreement With Can-Fite BioPharma

Freshfields Bruckhaus Deringer advised Ewopharma on the deal.

Ewopharma, a pharmaceutical marketing organization based in Schaffhausen, Switzerland, signed a licensing agreement for two compounds/new chemical entities (NCE’s) developed by Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases. 

The exclusive distribution agreement foresees that Ewopharma will have the exclusive right to market and sell one NCE (Piclidenoson) in Central Eastern European (CEE) countries and another one (Namodenoson) in CEE countries and Switzerland respectively. In return, the company will pay to Can-Fite 2.25 million US dollars upfront with up to an additional 40.45 million US dollars payable upon the achievement of regulatory and sales milestones plus 17.5 percent royalties on net sales. Further, Ewopharma will be granted the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.

Freshfields advised on all legal cross-border aspects of the licensing deal. The Freshfields core team comprised Jochen Dieselhorst (Picture) and Philipp Lehmann (both Corporate).

Involved fees earner: Jochen Dieselhorst – Freshfields Bruckhaus Deringer LLP; Philipp Lehmann – Freshfields Bruckhaus Deringer LLP;

Law Firms: Freshfields Bruckhaus Deringer LLP;

Clients: Ewopharma;

Author: Federica Tiefenthaler